Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 80 of the 83 references it cites were found in a registry or an index.

Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects

Open access

Abstract

Platinum complexes are clinically used as adjuvant therapy of cancers aiming to induce tumor cell death. Depending on cell type and concentration, cisplatin induces cytotoxicity, e.g., by interference with transcription and/or DNA replication mechanisms. Additionally, cisplatin damages tumors via induction of apoptosis, mediated by the activation of various signal transduction pathways, including calcium signaling, death receptor signaling, and the activation of mitochondrial pathways. Unfortunately, neither cytotoxicity nor apoptosis are exclusively induced in cancer cells, thus, cisplatin might also lead to diverse side-effects such as neuro- and/or renal-toxicity or bone marrow-suppression. Moreover, the binding of cisplatin to proteins and enzymes may modulate its biochemical mechanism of action. While a combination-chemotherapy with cisplatin is a cornerstone for the treatment of multiple cancers, the challenge is that cancer cells could become cisplatin-resistant. Numerous mechanisms of cisplatin resistance were described including changes in cellular uptake, drug efflux, increased detoxification, inhibition of apoptosis and increased DNA repair. To minimize cisplatin resistance, combinatorial therapies were developed and have proven more effective to defeat cancers. Thus, understanding of the biochemical mechanisms triggered by cisplatin in tumor cells may lead to the design of more efficient platinum derivates (or other drugs) and might provide new therapeutic strategies and reduce side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers3011351

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The targets of CDDP.
Figure 1. The targets of CDDP.CC BY · PubMed Central
Figure 2. Cellular interactions of CDDP: (1) reactive oxygen species; (2) DNA; (3) TNF; (4) mitochondria; (5) p53; (6) calcium signaling; (7) caspases; (8) multidrug resistant proteins.
Figure 2. Cellular interactions of CDDP: (1) reactive oxygen species; (2) DNA; (3) TNF; (4) mitochondria; (5) p53; (6) calcium signaling; (7) caspases; (8) multidrug resistant proteins.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 83 references

Research works printed but not linked: 3

  1. Trevisan, 2004, Erythrocyte aminolevulinic acid dehydratase inhibition by cisplatin, Toxicol. Lett., 152, 105
  2. Chattopadhyay, 2010, Metal complexes in medicine with a focus on enzyme inhibition, Curr. Opin. Chem. Biol., 14, 255, 10.1016/j.cbpa.2009.11.015 · DOI · Paper page
  3. Florea, A.-M., and Büsselberg, D. (2011). Cisplatin as an anti-tumour drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers, in press.

Cited by

See all 1,759

Metadata

Authors
Florea, A.-M., & Büsselberg, D.
Affiliations
  • Heinrich Heine University Düsseldorf (DE)
  • Weill Cornell Medical College in Qatar (QA)
Corresponding author
Büsselberg, Dietrich
Venue
Cancers
Publisher
MDPI AG
Published
2011-03-15
Volume
3
Issue
1
Pages
1351-1371
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2073131323
Cited by
1,759
References
83
Citations by year
2026: 65 · 2025: 111 · 2024: 154 · 2023: 148 · 2022: 165 · 2021: 177 · 2020: 195 · 2019: 176 · 2018: 133 · 2017: 129 · 2016: 100 · 2015: 82 · 2014: 70 · 2013: 28 · 2012: 21
FWCI
19.39
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
cisplatin, platinum complexes, apoptosis, DNA replication inhibition, calcium signaling, death receptor signaling, mitochondrial apoptosis, drug resistance, neurotoxicity, nephrotoxicity, myelosuppression, combination chemotherapy, DNA repair, drug efflux, cellular uptake, platinum derivatives

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. https://app.cochat.ai/papers/10.3390/cancers3011351
The paper
Florea, A.-M., & Büsselberg, D. (2011). Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers. https://doi.org/10.3390/cancers3011351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.